HOME >> BIOLOGY >> NEWS
Bacteria Becoming Increasingly Resistant To Antibiotics, But New Vaccines Are On The Horizon

LOS ANGELES (January 11, 1998) -- Streptococcus pneumoniae, bacteria that can cause life-threatening infections in adults and especially children, are rapidly becoming resistant to penicillin and cephalosporins such as ceftriaxone, the most widely used antibiotics currently available to treat bacterial infections, according to Moshe Arditi, M.D., author of an article in the November issue of Pediatrics and director of Cedars-Sinai Medical Center's Division of Pediatric Infectious Diseases.

Dr. Arditi said that while the bacteria are becoming resistant to antibiotics at "an astonishing rate," the penicillin-resistant strains of Streptococcus pneumoniae, or pneumococci, obtained from children with meningitis do not appear to be more virulent, or severe, than those that are susceptible to penicillin -- at least for now.

The Pediatrics article describes a three-year study of children suffering from pneumococcal meningitis. Researchers reviewed the charts of 180 children who were admitted to eight different children's hospitals between September 1, 1993 and August 31, 1996. Because one child had two episodes of infection, 181 episodes were documented in the findings. Dr. Arditi said the study looked at the clinical presentation, hospital course and outcome, taking into consideration the antibiotic resistance patterns of the pneumococci causing the infection. Researchers then determined whether there was a difference in outcome if the infecting organism was an antibiotic-resistant strain of pneumococcus.

"If you look at each year of the three-year study and look at the percentages, you see a dramatic increase in antibiotic resistance between the second year, for example, and the third year," said Dr. Arditi. "In the second year, the penicillin non-susceptible rate (intermediate susceptible and resistant organisms) was 13 percent. In the third year of the study, it jumped to 27 percent. For ceftriaxone, resistance in the first
'"/>

Contact: Sandra Van
sandy@vancommunications.com
1-800-396-1002
Cedars-Sinai Medical Center
11-Jan-1999


Page: 1 2 3 4

Related biology news :

1. Bacteria use molecular lasso to cop copper
2. Bacterial protein recycling factor possible key to new class of antibiotics
3. Bacteria spill their guts to aid researchers in quest for new antibiotics
4. Bacteria live in the esophagus!
5. Bacteria lingering in body may pose future food poisoning risks, Stanford study finds
6. Bacteria discoveries could resemble Mars, other planets
7. Bacterial relationships revealed
8. Bacteria-eating viruses may spread some infectious diseases
9. Bacteria convert food processing waste to hydrogen
10. Bacterial viruses make cheap easy vaccines
11. Bacterial infections alter allergic response

Post Your Comments:
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/19/2014)... , Dec. 18, 2014 Egenix, Inc. is ... been elected Chairman of the Board, to succeed Donald ... CEO, but will continue as a member of the Board.  ... has added to the company over almost twenty years, the ... The Board of Directors has established a Search Committee to ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
Breaking Biology Technology:Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
Cached News: